Clinical Trial Update: Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating autologous CD8+ and CD4+ T cells engineered with high-affinity KRASG12V-specific T cell receptors (FH-A11KRASG12V-TCR) for pat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• FH-A11KRASG12V-TCR

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Metastatic Malignant Solid Neoplasm | Phase 1 | Status: RECRUITING